These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 21484643

  • 1. [Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration].
    Kloos P, Niederberger H, Valmaggia C.
    Klin Monbl Augenheilkd; 2011 Apr; 228(4):340-4. PubMed ID: 21484643
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Jun; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F, Roider J, Hillenkamp J.
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [Abstract] [Full Text] [Related]

  • 6. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS.
    Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
    [Abstract] [Full Text] [Related]

  • 7. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM, Chen E, Mariani A, Major JC, SAVE Study Group.
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [Abstract] [Full Text] [Related]

  • 8. Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy.
    Jyothi S, Chowdhury HR, Chong V, Sivaprasad S.
    Eye (Lond); 2010 Jun; 24(6):1018-23. PubMed ID: 19893588
    [Abstract] [Full Text] [Related]

  • 9. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW, Kim MS, Kim ES, Yu SY, Kwak HW.
    Ophthalmologica; 2011 Jun; 225(3):169-75. PubMed ID: 21273795
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 14. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
    Kloos P, Bernasconi P, Estermann S, Bachmann B, Rutishauser Y, Thölen A.
    Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
    [Abstract] [Full Text] [Related]

  • 15. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.
    Viola F, Mapelli C, Villani E, Tresca Carducci F, Vezzola D, Ratiglia R.
    Eye (Lond); 2010 Aug; 24(8):1344-51. PubMed ID: 20339389
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F.
    Klin Oczna; 2010 Aug; 112(7-9):213-6. PubMed ID: 21121123
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M.
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.